Cancer - Profound Bio US Co.

A Phase 1/2 Study of PRO1107 in Patients with Advanced Solid Tumors

Drug

PRO1107

Condition

Ovarian cancer, fallopian tube cancer, endometrioid, clear cell carcinomas, endometrial cancer, triple-negative breast cancer, NSCLC, esophageal, gastroesophageal junction, or gastric adenocarcinoma, esophageal squamous cell carcinoma, and urothelial canc